For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.